BDTX_OUT_1 [2025-03-20 13:33:17 -0400] 2057 Bytes | 556 tokens | Cum: 556 tkns (6.95% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Black Diamond Therapeutics (BDTX) hit my radar screen, up to 2.0791 from a prev close of 1.72 Do you think its got more juice or is it lacking potential? It's 01:33:16 PM on Thursday March 20, 2025 ET (UTC-0400) and I have to decide: buy or sell!

Here's the first list of news for Black Diamond Therapeutics:

C1 - Today 10:42AM - Servier and Black Diamond sign deal for solid tumours therapy
C2 - Mar-19-25 07:00AM - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
C3 - Mar-06-25 04:09PM - Black Diamond: Q4 Earnings Snapshot
C4 - Mar-06-25 04:09PM 04:01PM - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C5 - Feb-19-25 09:15AM - NAYA Biosciences Announces Nomination of New Board Members
C6 - Jan-12-25 06:05AM - Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks
C7 - Nov-05-24 09:00AM - Black Diamond: Q3 Earnings Snapshot
C8 - Nov-05-24 09:00AM 08:00AM - Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Black Diamond Therapeutics (BDTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BDTX_OUT_3 [2025-03-20 13:33:25 -0400] 1038 Bytes | 260 tokens | Cum: 818 tkns (10.22% of 8k)
==========================================================================

Showing C1 (chunk 1 of 3): C1:
**Servier and Black Diamond sign deal for solid tumours therapy**
Date: Today 10:42AM
Source: (Pharmaceutical Technology)
URL: https://finance.yahoo.com/m/8c303abe-007a-3a59-865c-15dbcb75bf18/servier-and-black-diamond.html

Servier and Black Diamond Therapeutics have signed a licensing agreement for a targeted therapy, BDTX-4933, to treat solid tumours.

Servier will be responsible for the development and the global commercialisation of the therapy for several indications.

The focus will initially be on non-small cell lung cancer (NSCLC), with the possibility of extension to other solid tumour types.

Servier will pay Black Diamond $70m upfront, along with up to $710m in potential milestone payments based on development and commercial sales, plus royalties.

The small molecule targets alterations in RAS (rat sarcomas) and RAF (rapidly accelerated fibrosarcomas) present in solid tumo

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

BDTX_OUT_5 [2025-03-20 13:33:26 -0400] 1044 Bytes | 227 tokens | Cum: 1185 tkns (14.81% of 8k)
==========================================================================

Showing C1 (chunk 2 of 3): urs.

BDTX-4933 is undergoing Phase I clinical development. The ongoing first-in-human trial is assessing the therapy's tolerability, preliminary antitumour activity and safety, and determining the recommended dose for Phase II.

The study includes adults with advanced or metastatic cancers that exhibit mutations in the B-Raf proto-oncogene, serine/threonine-protein kinase (BRAF), CRAF or neuroblastoma RAS viral oncogene homolog.

Servier research and development executive vice-president Claude Bertrand stated: “Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies, as we believe we can serve more people by helping the right patients find the right treatment, at the right time.

“We look forward to accelerating the development of this therapy as a potential best-in-class treatment for cancer patients.”

Black Diamond develops MasterKey therapies en

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

BDTX_OUT_7 [2025-03-20 13:33:27 -0400] 890 Bytes | 259 tokens | Cum: 1446 tkns (18.07% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T13:42:55Z - Servier and Black Diamond sign deal for solid tumours therapies...
A2 - 2025-03-20T16:10:47Z - Black Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at Wedbush...
A3 - 2025-03-20T15:20:33Z - Black Diamond Therapeutics Sees Unusually High Options Volume (NASDAQ:BDTX)...
A4 - 2025-03-20T14:42:55Z - Servier and Black Diamond sign deal for solid tumours therapy...
A5 - 2025-03-20T10:21:00Z - Servier to develop and commercialise targeted solid tumour therapy, BDTX-4933...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BDTX_OUT_9 [2025-03-20 13:33:33 -0400] 1038 Bytes | 252 tokens | Cum: 1700 tkns (21.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Servier and Black Diamond sign deal for solid tumours therapies**Date: 2025-03-20Source: {'uri': 'pharmaceutical-technology.com', 'dataType': 'news', 'title': 'Pharmaceutical Technology'}URL: https://www.pharmaceutical-technology.com/news/servier-black-diamond-deal/Servier and Black Diamond Therapeutics have signed a licensing agreement for a targeted therapy, BDTX-4933, to treat solid tumours.

Servier will be responsible for the development and the global commercialisation of the therapy for several indications.

The focus will initially be on non-small cell lung cancer (NSCLC), with the possibility of extension to other solid tumour types.

Servier will pay Black Diamond $70m upfront, along with up to $710m in potential milestone payments based on development and commercial sales, plus royalties.

The small molecule targets alterations in RAS (rat sarcomas) and RAF (rapidly acce

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

BDTX_OUT_11 [2025-03-20 13:33:35 -0400] 1220 Bytes | 353 tokens | Cum: 2142 tkns (26.77% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T11:00:00Z - Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
B2 - 2025-01-29T18:00:00Z - BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
B3 - 2024-11-05T13:00:00Z - Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
B4 - 2024-10-07T20:01:00Z - Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
B5 - 2024-09-22T14:00:00Z - Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
B6 - 2024-09-14T07:30:00Z - Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDTX_OUT_13 [2025-03-20 13:33:40 -0400] 815 Bytes | 210 tokens | Cum: 2354 tkns (29.43% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/19/3045227/0/en/Servier-and-Black-Diamond-Therapeutics-Announce-Global-Licensing-Agreement-for-BDTX-4933-A-Targeted-Oncology-Therapy.htmlServier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

BDTX_OUT_15 [2025-03-20 13:33:42 -0400] 1089 Bytes | 287 tokens | Cum: 2726 tkns (34.08% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 18, 2025, Black Diamond Therapeutics, Inc. (the Company) entered into a License Agrmt (the License Agrmt) with Servier Pharmaceuticals LLC (Servier). Under the terms of the License Agrmt, the Company gr...

S2 - 2025-03-19 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 18, 2025, Black Diamond Therapeutics, Inc. (the Company) entered into a License Agrmt (the License Agrmt) with Servier Pharmaceuticals LLC (Servier). Under the terms of the License Agrmt, the Company gr...

S3 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis should be read in conjunction with our audited CONS financial statements and related notes included elsewhere in this Annual Report. This ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDTX_OUT_17 [2025-03-20 13:33:53 -0400] 7003 Bytes | 1951 tokens | Cum: 4680 tkns (58.50% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| Volume: 17,411,035 | SMA50: -3.66% | Market Cap: 117.86M | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| Avg Volume: 2.70M | SMA200: -44.08% | Shs Outstand: 56.64M | Short Float: 17.17% | Employees: 24 | EPS Surprise: 11.03% |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| Rel Volume: 10.64 | Perf Week: 26.07% | Shs Float: 43.16M | Short Ratio: 2.74 | Debt/Eq: 0.27 | P/E: - |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| RSI (14): 55.09 | Perf Month: -12.23% | Inst Own: 75.06% | Short Interest: 7.41M | Sales Y/Y TTM: - | Earnings: Mar 06 AMC |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| ATR (14): 0.23 | Perf Quarter: -21.21% | Insider Own: 23.83% | Beta: 2.79 | ROE: -69.67% | |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+
| SMA20: 11.03% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -68.26% | |
+--------------------+-----------------------+----------------------+-------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Hatzis-Schoch Brent (SEE REMARKS) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 175000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Jones Erika (SEE REMARKS) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 125000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Buck Elizabeth (CHIEF SCIENTIFIC OFFICER) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 175000 shares at $0 (D)

Inside Trans: Black Diamond Therapeutics, Inc. (BDTX) by Yurasov Sergey (CHIEF MEDICAL OFFICER) on 2025-01-30
- Common Stock: 75000 shares at $0 (D) Footnote: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
- Stock Option (Right to Buy): 200000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Black Diamond Therapeutics, Inc. Common Stock
Market Cap: 97459021.84
Shares Outstanding: 56662222
Sector: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -69676000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.075
Average Volume: 6150082.35
30-Day High: 2.37
30-Day Low: 1.65

[Detailed Financials: TTM 2024]
- Total Assets: $122,640,000.0
- Total Liabilities: $39,355,000.0
- Total Equity: $83,285,000.0
- Current Assets: $101,176,000.0
- Current Liabilities: $20,573,000.0

[Income Statement: TTM 2024]
- Revenue: $0
- Net Income: $-69,676,000.0
- Operating Income: $-78,781,000.0
- Earnings Per Share (EPS): -1.27

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-19,788,000.0

[Detailed Financials: FY 2024]
- Total Assets: $122,640,000.0
- Total Liabilities: $39,355,000.0
- Total Equity: $83,285,000.0
- Current Assets: $101,176,000.0
- Current Liabilities: $20,573,000.0

[Income Statement: FY 2024]
- Revenue: $0
- Net Income: $-69,676,000.0
- Operating Income: $-78,781,000.0
- Earnings Per Share (EPS): -1.27

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-19,788,000.0
==== END OF FINANCIAL REPORT ====

Now we've reached the end of the analysis.
You are now requested to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BDTX_OUT_19 [2025-03-20 13:33:57 -0400] 561 Bytes | 131 tokens | Cum: 5049 tkns (63.11% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BDTX_IN_21 [2025-03-20 13:33:57 -0400] 126 Bytes | 29 tokens | Cum: 5139 tkns (64.24% of 8k)
==========================================================================

====================================
[2025-03-20 10:33:57] # Analysis Completed
Elapsed Time: 42.16 seconds